Archives
-
Type III Collagen Restricts Breast Cancer Progression
2026-09-19
This study identifies type III collagen (Col3) as a tumor-restrictive component of the breast cancer microenvironment. By combining fibroblast-derived matrices, patient tissue analysis, TCGA bioinformatics, 3D cultures, and mouse models, the authors show that increased Col3 relative to type I collagen is associated with less aggressive disease and reduced tumor growth and metastasis.
-
Z-VAD-FMK in Necroptosis Assay Design
2026-09-18
Z-VAD-FMK is more than an apoptosis inhibitor: it can serve as a causal probe for separating caspase-dependent death from necroptosis. This article translates recent hepatic stellate cell findings into practical assay decisions, controls, and interpretation strategies.
-
Electroporation Enables CRISPR Editing in Mouse Zygotes
2026-09-18
Hashimoto and Takemoto showed that electroporation can deliver Cas9 mRNA and guide RNA into mouse zygotes without removing the zona pellucida, providing a scalable alternative to embryo microinjection. Their optimized workflow supported both Fgf10 disruption and ssODN-mediated knock-in, while linking pulse intensity and embryo survival to practical protocol design.
-
Neticonazole Hydrochloride: Research Workflows
2026-09-17
Neticonazole Hydrochloride supports two complementary research tracks: validated topical antifungal workflows and exploratory colorectal cancer studies focused on exosome inhibition and apoptosis. This guide converts diagnostic evidence into practical assay design, formulation, controls, and troubleshooting steps.
-
Notch Blockade Sensitizes TNBC to Checkpoint Therapy
2026-09-17
Shen et al. show that suppressing Notch-dependent cytokine programs can remodel the tumor immune microenvironment and improve sequential immune checkpoint blockade in triple-negative breast cancer. The work links tumor-cell signaling to macrophage recruitment, cytotoxic T-cell activation, and suppression of lung metastasis, providing a mechanistic framework for combination immunotherapy studies.
-
EZ Cap™ Cas9 mRNA (m1Ψ) for Precise Editing
2026-09-16
EZ Cap™ Cas9 mRNA (m1Ψ) combines Cap1 capping, m1Ψ modification, and a poly(A) tail for transient Cas9 expression in mammalian-cell editing workflows. This guide translates those design features into practical delivery, assay-selection, troubleshooting, and nuclear-export control strategies.
-
Predictive siRNA Codelivery with Netarsudil
2026-09-16
Slaughter and colleagues developed a quantitative workflow for predicting whether ionizable drugs can complex siRNA and support co-encapsulation in lipid-like nanoparticles. Netarsudil emerged as a high-performing candidate and, in fibrotic human trabecular meshwork cells, enabled CTGF-targeting siRNA delivery associated with reduced CTGF mRNA and actin network density.
-
Hoechst 33342 for Senescence Imaging Workflows
2026-09-15
Hoechst 33342 supports consistent nuclear segmentation in live and fixed human dermal fibroblast assays, helping connect cell counts and morphology with mitochondrial-quality measurements. This workflow shows how to use the dye as a quantitative imaging and flow-cytometry reference without mistaking nuclear labeling for a standalone senescence marker.
-
EGCG: Mechanisms, Evidence, and Research Workflow
2026-09-15
(-)-Epigallocatechin gallate (EGCG) is a green tea catechin used in apoptosis assay, antiviral research, cancer chemoprevention, and biomaterial studies. Evidence supports pathway-level activity, while the strongest recent intervertebral disc evidence concerns an EGCG-containing hydrogel microsphere rather than free EGCG monotherapy.
-
YC-1 in Neuroinflammation Assay Design
2026-09-14
Explore how YC-1 can function as a mechanistic control in hypoxia and cancer research while clarifying what a recent trigeminal neuralgia study does—and does not—establish. This article translates the study’s Ca2+-CGRP/SP-Piezo2 findings into practical assay-design decisions without overstating cross-domain evidence.
-
Atrial Natriuretic Peptide in Cell Assays
2026-09-14
This scenario-based guide explains how to incorporate Atrial Natriuretic Peptide (ANP) (C49H84N20O15S), rat (SKU A1009) into cell viability, proliferation, and cytotoxicity workflows. It focuses on controls, formulation, handling, interpretation, and evidence-based product selection for cardiovascular and translational research.
-
Necrostatin-1: A Translational Probe for Necroptosis
2026-09-13
Necrostatin-1 is more than a reagent for blocking regulated necrotic death: it is a mechanistic probe for separating RIP1-dependent necroptosis from ferroptosis, autophagy, and apoptosis in complex disease models. This thought-leadership article examines how a RIP1 kinase inhibitor can strengthen cell-death studies inspired by the 2023 3-bromopyruvate/cetuximab resistance study, while defining practical assay parameters, translational opportunities in tissue injury and acute kidney injury research, and the limitations that must be addressed before pathway modulation can inform therapeutic strategy.
-
Small-Molecule Control of Pancreatic Ductal Organoids
2026-09-12
Liao and colleagues developed a small-molecule culture strategy that improves the initiation and long-term expansion of pancreatic ductal organoids while retaining heterogeneous ductal and acinar populations. The work provides a practical organoid platform for pancreatic disease modeling, drug screening, and investigation of ductal–acinar plasticity.
-
GCLC Truncation and Delayed Age-Related Cataract
2026-09-11
Wei et al. identify age-related truncation of the γ-glutamylcysteine ligase catalytic subunit (GCLC) at Asp499 as a mechanism that may drive the decline of lens glutathione and accelerate cataract formation. In a D499E knock-in mouse model, preventing this truncation preserved the glutathione defense system and substantially delayed age-related cataract, providing a mechanistic basis for prevention-oriented research.
-
Ginsenoside Rg6 Reverses Cisplatin Resistance in EOC
2026-09-11
A 2025 study links cisplatin resistance in epithelial ovarian cancer cells to altered fucosylation and identifies the GRB2–ERK1/2–mTOR axis as a mechanistic connection to autophagy. Its findings suggest that ginsenoside Rg6 may improve cisplatin activity by promoting autophagy, restoring CTR1-associated drug uptake, and reducing protein fucosylation, although validation beyond cell models is still needed.